Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of PCSK9 Monoclonal Antibody Very Early Administered in Hospital to Reduce Cardiovascular Events in Acute Myocardial Infarction (IMMEDIATE -MI)

NCT07208006 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07208006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07208006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of PCSK9 Monoclonal Antibody Very Early Administered in Hospital to Reduce Cardiovascular Events in Acute Myocardial Infarction (IMMEDIATE -MI)
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
January 1, 2026
Completion date
October 31, 2028
Enrollment
1,518 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction (ami)